GLOW
GHK-Cu + BPC-157 + TB-500 research blend
Vendor/community blend name for a co-formulation of GHK-Cu, BPC-157 and TB-500; evidence comes from the individual components rather than the three-peptide blend itself.
Reference dose
1.4–4.2 mg per injection; 2.8 mg is a commonly cited reference point
Source-specific educational reference, not an individualized recommendation.
Reference schedule
Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Components
3 peptides
GHK-Cu + BPC-157 + TB-500.
Blend-level trials
None identified
Published evidence is component-level rather than for the three-way co-formulation.
Standard formula
No
Commercial mass ratios and total vial strength can vary.
Regulatory status
Not approved
GLOW is a research blend designation, not an FDA-approved product.
What it is
GLOW is a community and vendor name for a multi-peptide research vial containing GHK-Cu, BPC-157 and TB-500.
The components remain separate chemical entities inside the formulation; GLOW is not a new fusion peptide or standardized pharmaceutical molecule.
Research focus
How it works
GLOW combines three chemically distinct peptides that are discussed across skin, matrix-remodelling and tissue-repair research. Any rationale for combining them is extrapolated from separate component studies; the blend has not established its own pharmacology, dose-response or clinical efficacy.
Important context
GLOW is not a standardized drug or single molecule. Commercial blend ratios vary, and the evidence for GHK-Cu, BPC-157 and TB-500 must be read separately. A positive finding for one component does not become evidence for the blend.
What it is studied for
Skin and extracellular-matrix interest comes primarily from GHK-Cu research.
Recovery and connective-tissue interest comes primarily from BPC-157 and thymosin-beta-4-related preclinical literature.
The blend concept assumes those research themes may complement one another, but additive or synergistic benefit has not been established.
More contextThree components, three different evidence basesSee the deeper context, evidence details and practical distinctions behind this profile.
GHK-Cu has the strongest direct human evidence of the three, but that evidence is mainly topical skin research rather than injected multi-peptide blends.
BPC-157 is supported primarily by animal and laboratory studies, with only very small human pilot data. TB-500 is a thymosin-beta-4 fragment for which FDA reports no identified human drug-exposure data; full-length thymosin beta-4 studies should not be relabelled as TB-500 evidence.
- No controlled human trial of the GHK-Cu + BPC-157 + TB-500 blend was identified for this profile.
- No standardized GLOW composition, mass ratio, dose or treatment schedule is established in an approved label or pharmacopeial specification.
- Injectable GHK-Cu, BPC-157 and TB-500 each carry evidence and safety limitations that remain relevant when they are co-formulated.
- Combining components also creates unanswered formulation questions such as stability, compatibility and whether one component changes another's exposure.
Why people are interested
What makes GLOW worth researching.
GHK-Cu component evidence
Skin & matrix rationale
GHK-Cu contributes the strongest direct skin-related human evidence, including small topical studies involving collagen and wrinkle-related outcomes.
BPC-157 component evidence
Tissue-repair rationale
BPC-157 has a broad animal literature around gastrointestinal and connective-tissue repair models, but direct human efficacy evidence remains very limited.
TB-500 / Tβ4 context
Thymosin-related rationale
TB-500 is discussed through thymosin-beta-4-related repair biology, but evidence from full-length thymosin beta-4 cannot simply be assigned to the TB-500 fragment.
Blend evidence absent
The combination itself
There is no established evidence that co-formulating all three components improves efficacy, changes pharmacokinetics or produces a better benefit-risk profile than using any component alone.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Human topical + preclinical
GHK-Cu
Small human topical studies and a larger mechanistic literature support interest in skin and extracellular-matrix biology, but this does not validate injected GLOW.
Mostly preclinical
BPC-157
Animal and laboratory studies dominate. Published human evidence remains extremely limited and does not establish popular recovery dosing.
Preclinical / indirect human context
TB-500
FDA reports no identified human drug-exposure data for the TB-500 fragment. Human full-length thymosin-beta-4 studies are indirect evidence only.
No controlled blend evidence identified
GLOW co-formulation
The three-component mixture does not have its own validated human dose, pharmacokinetic profile, efficacy dataset or safety dataset.
Human research
No controlled human trial of the three-component GLOW blend was identified for this profile.
Human evidence for individual components is uneven: GHK-Cu has small topical skin studies, BPC-157 has very limited pilot human data, and FDA reports no identified human exposure data for TB-500 drug products.
Those component findings cannot be combined mathematically or rhetorically into a human efficacy claim for GLOW.
Preclinical research
Each component has its own preclinical literature covering different aspects of extracellular-matrix biology, tissue repair, vascular signalling or inflammation.
No direct preclinical co-formulation study of all three GLOW components was identified for this profile.
Without direct combination data, it is unknown whether the components are additive, neutral, antagonistic or altered by being co-formulated.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
1.4–4.2 mg per injection; 2.8 mg is a commonly cited reference point
Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks
The range above is The Pep Report research reference for GLOW. Blend composition and component ratios can vary, so confirm the exact formulation before using any concentration calculation.
Calculator connection
This profile does not currently use a vial or pen calculator. Follow the formulation-specific information shown for the product or reference you are using.
A total vial mass is not enough to calculate a meaningful component dose. Two GLOW vials can have the same total mg but different amounts of GHK-Cu, BPC-157 and TB-500, so the generic single-peptide vial calculator is intentionally disabled.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Storage belongs to the exact formulation. Generic advice can orient you, but the label, pharmacy directions or formulation-specific stability data should determine the final temperature and usable-life limits.
Pens
Treat a pen as a finished drug-device product: protect it from unnecessary heat and light, do not freeze unless the exact label explicitly permits it, and use that device's own unopened and in-use storage window.
Vials
Treat dry and reconstituted vials as different stability states. Refrigeration after mixing is common for some formulations but is not a universal peptide rule.
Product-specific notes
There is no approved GLOW label establishing standardized storage or stability instructions.
Co-formulated peptides can have formulation-specific stability requirements; supplier claims should not be assumed to apply across different blend ratios or excipients.
Practical reference
Formats
Multi-peptide blend vial
Reconstitution & units
Adding liquid changes the concentration of every component simultaneously, but each component's concentration depends on its own starting mass.
A total-mg vial value does not reveal component concentrations unless the exact GHK-Cu:BPC-157:TB-500 composition is known.
The generic single-peptide vial calculator is disabled because it accepts one total peptide mass and would obscure the individual component doses.
A future blend calculator should require the exact mass of every component before showing component-level concentration arithmetic.
Safety, status & open questionsOpen the practical cautionsGLOW is a research blend name, not an FDA-approved medicine. Its component peptides have very different evidence bases, and the blend itself should not be described as clinically proven for skin, healing, recovery or any other outcome.
Open questions
There is no standardized GLOW formulation, so results or dosing claims for one vendor's vial may not map to another.
Blend pharmacokinetics, component interactions and formulation stability have not been clinically characterized.
The human safety profile of repeated co-administration of all three components is not established.
Most positive recovery claims rely on extrapolation from preclinical component studies rather than blend trials.
Regulatory notes
GLOW is not an FDA-approved drug or standardized pharmaceutical formulation.
Injectable GHK-Cu is listed by FDA among compounded bulk substances that may present significant safety risks, including potential immunogenicity related to aggregation and peptide impurities.
BPC-157-related and TB-500-related bulk substances were reviewed in FDA's July 2026 Pharmacy Compounding Advisory Committee process.
Practical notes
There is no direct human safety dataset for the three-component blend.
Injectable GHK-Cu carries FDA-noted immunogenicity concerns related to aggregation and peptide impurities, with limited human injectable safety data.
BPC-157 and TB-500 have major human-evidence gaps, and research/compounded injectable products add identity, purity, sterility and concentration risks.
Unknown compatibility or stability of a specific co-formulation can add uncertainty beyond the risks of each component separately.
Common mistakes
Treating three separate component literatures as though they were a clinical trial of GLOW.
Quoting a total blend dose without stating the component ratio.
Using topical GHK-Cu evidence to imply that injected GLOW has proven skin benefits.
Citing full-length thymosin-beta-4 human research as direct TB-500 or GLOW evidence.
Using a generic vial calculator that cannot display component-level amounts.
Common questions
Has GLOW itself been clinically studied?
No controlled human study of the GHK-Cu + BPC-157 + TB-500 blend was identified for this profile. The available evidence comes from the components separately.
Is every GLOW vial the same formula?
No. GLOW is not a standardized pharmaceutical formulation, and commercial ratios and total vial strength can vary.
Why is there no vial calculator button?
The current calculator accepts one peptide mass. For a blend, that could hide different component ratios and produce a misleading total-mg result.
Does GHK-Cu skin evidence prove GLOW improves skin?
No. Topical GHK-Cu findings are component- and route-specific and do not validate an injected three-peptide blend.
Related peptides & blends
GHK-Cu
Naturally occurring copper-binding tripeptide researched for collagen signalling, skin quality, extracellular-matrix remodelling and tissue repair.
Open reference →BPC-157
Synthetic 15-amino-acid peptide with extensive animal research in tissue-repair and gastrointestinal models but very limited human evidence.
Open reference →TB-500
Synthetic thymosin-beta-4-related fragment researched for wound and tissue-repair biology, with no established human clinical evidence for the fragment itself.
Open reference →KLOW
Four-peptide research blend combining GHK-Cu, BPC-157, TB-500 and KPV; the evidence base belongs to the individual components rather than the co-formulation.
Open reference →BPC-157 / TB-500 (Wolverine)
Research blend name for BPC-157 + TB-500; one 2026 rat tendon study tested the combination directly, but no controlled human blend trial has established efficacy or dosing.
Open reference →References
GHK-Cu topical anti-wrinkle evidence — review
BioImpacts / PMC · 2025
BPC-157 human IV safety pilot
PubMed · 2025
FDA — compounded bulk substances that may present significant safety risks
U.S. FDA · 2026
FDA July 2026 PCAC review — BPC-157 and TB-500-related substances
U.S. FDA · 2026
BPC-157 in orthopaedic sports medicine — systematic review
PMC · 2025